Outcomes and toxicities of immune checkpoint inhibitors in patients with lung cancer and pre-existing autoimmune disease
{{output}}
Background: Patients with pre-existing autoimmune disease (PAD) are often excluded from immune checkpoint inhibitor (ICI) clinical trials in thoracic oncology, creating uncertainty regarding their real-world safety and effectiven... ...
